Loading
A phase 2 trial of Fludarabine, Bendamustine in hodgkin lymphoma, run by Tessa Therapeutics, active and no longer recruiting.
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) is a phase 2 interventional study registered as NCT04268706 by Tessa Therapeutics, with 97 participants planned, started 2021-02-01 and due to reach its primary completion in 2025-05. Interventions recorded: CD30.CAR-T, Fludarabine, Bendamustine. Conditions listed: Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric. No results are recorded here; the registry entry is the source.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Bendamustine, Fludarabine.
Shares Bendamustine, Fludarabine.
Shares Fludarabine, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Bendamustine, Hodgkin lymphoma.